Uncategorized

Memo Therapeutics AG Raises CHF 25 Million Series C Financing to Complete Phase II Clinical Development of AntiBKV for BKV Infection in Renal Transplant Patients

Memo Therapeutics AG, a late-stage biotech company developing best-in-class therapeutic antibodies, announced the closing of a CHF25 million Series C financing led by Pureos Bioventures.

Memo Therapeutics AG Raises CHF 25 Million Series C Financing to Complete Phase II Clinical Development of AntiBKV for BKV Infection in Renal Transplant Patients Read More »

Kodiak Sciences Announces First Time Presentation of Primary Endpoint Data From Tarcocimab Tedromer Phase 3 GLOW Study in Patients With Diabetic Retinopathy at American Academy of Ophthalmology Annual Meeting

Kodiak Sciences Inc announced that data from tarcocimab tedromer will be presented during the annual meeting of the American Academy of Ophthalmology to be held November 3-6 in San Francisco.

Kodiak Sciences Announces First Time Presentation of Primary Endpoint Data From Tarcocimab Tedromer Phase 3 GLOW Study in Patients With Diabetic Retinopathy at American Academy of Ophthalmology Annual Meeting Read More »

Scroll to Top